News

Pharmaceutical News

Pharmaceutical News

FDA Grants Priority Review to Gilead Sciences' Hepatitis C Combination Drug

  • Date: 01-07-2016 --
  • 01/05/16, Pharmaceutical Business Review
  • body: The U.S. Food and Drug Administration (FDA) has granted priority review to Gilead Sciences' experimental hepatitis C combination drug. Gilead filed a new drug application for the treatment, a combination of the company's Sovaldi with velpatasvir, in October last year. A final decision from the FDA is expected by June 28.
  • URL: http://multibriefs.com/ViewLink.php?i=568d303a22f1f